Bacteria and inflammatory bowel disease

Current Opinion in Infectious Diseases

Volumn 13, Issue 5, 2000, Pages 503-509

  Martin, Helen Mary ^a   Rhodes, Jonathan Michael ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTEROIDES FRAGILIS; CROHN DISEASE; ENTERITIS; ESCHERICHIA COLI; EUBACTERIUM; HELICOBACTER PYLORI; INTESTINE FLORA; NONHUMAN; REVIEW; ULCERATIVE COLITIS;

EID: 0033759683     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200010000-00012     Document Type: Review

References (63)

1. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice
2. Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel diseases
3. Probiotics: From myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials
4. Probiotics and gut inflammation
5. Chronic interstitial enteritis
6. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli
7. Characterisation of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis
8. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease
9. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique
10. Probiotics and inflammatory bowel diseases
11. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease
12. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls
13. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls
14. Presence of eubacteria in biopsies from Crohn's disease inflammatory lesions as determined by 16S rRNA gene-based PCR
15. Association between intraepithelial Escherichia coli and colorectal cancer
16. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease
17. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease
18. Absence of Mycobacterium paratuberculosis DNA in intestinal tissues from Crohn's disease by nested polymerase chain reaction
19. Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease
20. Mycobacteria in the intestine of Japanese patients with inflammatory bowel disease
21. Controlled trial of antituberculosis chemotherapy in Crohn's disease: A five year follow up study
22. Antibacterial therapy for Crohn's disease: A review emphasizing therapy directed against mycobacteria
23. A meta-analysis of antimycobacterial therapy for Crohn's disease
24. Open label trial of oral clarithromycin in active Crohn's disease
25. Influence of Helicobacter pylori infection on the phenotype of Crohn's disease
26. A novel urease-negative Helicobacter species associated with colitis and typhilitis in IL-10-deficient mice
27. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease
28. Focally enhanced gastritis: A frequent type of gastritis in patients with Crohn's disease
29. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease
30. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in inflammatory bowel disease: Prevalence and diagnostic role
31. Lectins, colitis and colon cancer
32. Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae
33. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope
34. Identification of a novel mycobacterial histone HI homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease
35. Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: Do they react with different antigens?
36. Intestinal inflammation and the gut microflora
37. Modulatory effects of the colonic milieu on neutrophil oxidative burst: A possible pathogenic mechanism of ulcerative colitis
38. Formylmethionyl-leucylphenylalanine and the SOS operon in Escherichia coli: A model of host-bacterial interactions
39. Enzymes degrading bacterial chemotactic F-met peptides in human ileal and colonic mucosa
40. Evidence that colitis is initiated by environmental stress and sustained by fecal factors in the cotton-top tamarin (Sanguinis oedipus)
41. Novel intestinal Helicobacter species isolated from cotton-top tamarins (Sanguinis oedipus) with chronic colitis
42. The germfree state prevents development of gut and joint inflammatory bowel disease in HLA-B27 transgenic rats
43. Correlation of cecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease
44. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats
45. 2microglobulin transgenic rats
46. Colitis in HLA-B27/beta 2 microglobulin transgenic rats
47. Lactobacillus spp. prevents development of enterocolitis in interleukin-10 gene deficient mice
48. Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice
49. The role of antibiotics in Crohn's disease
50. Combination ciprofloxacin and metronidazole for active Crohn's disease
51. Dietary carbohydrates and the colonic microflora
52. Impact on the composition of the fecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis
53. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative
54. The role of probiotic cultures in the control of gastrointestinal health
55. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression
56. Oral bacteriotherapy as maintenance treatment in patients with chronic ponchitis: A double-blind, placebo-controlled trial
57. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
58. Prolonged intake of fructo-oligosaccharides induces short-term elevation of lactic-acid producing bacteria and a persistent increase in cecal butyrate in rats
59. Inulin and oligofructose: What are they?
60. Effect of enteral inulin on the pouch disease activity index and on epithelial gene expression within the ileoanal pouch: A randomized, placebo-controlled crossover study
61. Geminated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model
62. The contribution of sulphate-reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis
63. Identification of a novel bacterial sequence associated with Crohn's disease